Aim: To report our experience on CD34+/ASCT for multiple sclerosis (MS) treatment. Design and methods. Patients with advanced secondary progressive (SP) or relapsing-remitting (RR) MS and confirmed worsening of the extended disability status scale (EDSS) in the previous year despite interferon or other immunotherapies were included. Peripheral blood stem cells were obtained by leukaphereses after mobilization with cyclophosphamide (Cy) and G-CSF. CD34+ selection was performed by means of Isolex 300 or CliniMACS devices. BCNU, Cy and ATG were administered as conditioning regimen. Results: Sixteen patients (9 SPMS and 7 RRMS) with a median EDSS of 6.0 (4.5-6.5) and a median of 3 (1-7) relapses in the previous year were included. Mobilization was unsuccessful in one. During mobilization, one patient presented a transient neurologic deterioration. CD34+/ASCT was performed in 15 patients. Main complications during ASCT were engraftment syndrome in three patients, CMV reactivation in one, and neurologic deterioration coinciding with high-fever related to ATG in two. Haematological recovery was fast and complete in all cases. After a median follow up of 34 months (range, 6 -54), EDSS had progressed in two patients, improved in four and remained stable in nine. Despite withdrawal of all immunosuppressive therapy only three patients presented relapses that required treatment. Eleven out of 15 patients had problems with urinary sphincter control before SCT. At one year 7 had clearly improved this function All these facts contributed to subjectively improve the patients' quality of life; but no validated instruments of measurement of this improvement were used. MRI showed disappearance of enhanced T1 lesions but CSF oligoclonal bands persisted in all evaluated cases. Conclusions: Our results show that CD34+/ASCT using BCNU, Cy and ATG as conditioning regimen has an acceptable toxicity and probably reduces the progression of the disease.
Oral Session: Cytokines / Gene therapy O159 All-trans retinoic acid skews monocyte differentiation into IL-12 secreting dendritic-like cells with potent functional activities M. Mohty, S. Morbelli, D. Blaise, D. Isnardon, D. Sainty, B. Gaugler, D. Olive (Marseille, F) Retinoid derivatives are essential agents for multiple biologic processes. All-trans retinoic acid (ATRA) proved to be a potential drug for the treatment of acute promyelocytic leukemia. Numerous immune system dysfunctions can occur in case of retinoid deficiency including atrophy or enlargement of secondary lymphoid organs, changes in lymphocyte counts, altered T, B and NK cell functions, and altered cytokine production. Dendritic cells (DC) play a key role in the initiation of the immune response and are considered promising targets for immunotherapy. Because of their central role in controlling immunity and the wide effects of retinoids on the immune system homeostasis, we assayed the ability of ATRA to influence the differentiation of DCs from circulating peripheral blood monocytes. Here we show that ATRA (10-12 M) and GM-CSF could drive the differentiation of monocytes into dendritic-like cells (ATRA-DC). ATRA-DCs exhibited DC morphology, had a phenotype of immature DCs, with the expression of CD1a, and up-regulation of adhesion and costimulatory molecules. ATRA-DCs could induce a proliferative response in naive CD4+ T cells. Although ATRA-DCs retained their antigen-capture capacity as shown by FITC-Dextran endocytosis, they secreted IL-12p70 without the need for any maturation agent. In addition, ATRA-DCs could drive T cells towards an IL-12-dependent Th1 response with secretion of IFNgamma. Collectively, this is the first study on the effects of ATRA on DC differentiation and functional properties, giving new insights into the mechanisms of action of ATRA. DCs appear to be potential targets for ATRA. The latter provides framework for the development and refinement of ATRA-based immunotherapeutic interventions under stringent biological and cellular monitoring.
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TNF polymorphisms are associated with toxic but not with aGvHD complications in the recipients of allogeneic sibling hematopoietic stem cell transplantation K. Bogunia-Kubik, M. Polak, A. Lange (Wroclaw, PL) Previous reports show an association between TNF genotype and aGvHD. We wanted to determine whether this association is direct or due to TNF genotype associated susceptibility to toxic complications. We analysed NcoI polymorphism within the promoter/enhancer region of TNF-alpha and the first intron of TNF-beta gene in seventy patients (ALL: 22; AML: 17; CML: 26; MDS: 2; NHL: 3; F/M: 26/44; age: 2-49, median 20), which had been transplanted from HLA identical sibling donors and in 130 healthy individuals. All the patients received myeloablative conditioning regimen. It was found that patients heterozygous for one or both TNF genes suffered more frequently from severe (grade III-IV) toxic complications than those carrying the other TNF genotypes (TNFA*1,2: 9/39 vs 1/31, p=0.018; TNFB*1,2: 20/39 vs 6/31, p=0.006; TNFA*1,2 and TNFB*1,2: 9/39 vs 0/31, p=0.003). Conversely, patients having TNFB*2,2 and/or TNFA*1,1 less frequently belonged to the group presented with severe toxic lesions (TNFA*1,1: 30/39 vs 29/31, p=0.055; TNFB*2,2 or TNFA*1,1/TNFB*2,2: 17/39 vs 22/31, p=0.020). These relations were independent of the severity of conditioning regimen. Additional analyses showed that TNFA*1,2 in TNFB*1,2 negative individuals (p=0.007) and TNFB*1,2 in those having TNFA*1,2 (p=0.002) associated with development of grade III-IV toxic lesions, whilst TNFB*2,2 and TNFA*1,1 in combined association fashion (p=0.005) played a protective role. However, no association was observed between TNF genotypes and aGvHD manifestation. These results imply that TNF polymorphisms strongly influence the susceptibility to toxic complications in patients after allogeneic HSCT.
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HLA-matching influences the production of the IL-1 family of cytokines in an alloimmune response H. Cullup, X.N. Wang, A.M. Dickinson (Newcastle-upon-Tyne, UK) The cytokines interferon-gamma and IL-2 are produced in the alloimmune response involved in the production of alloreactive CTLs in a mixed lymphocyte response (MLR). These CTLs are generated by allorecognition of mismatched between MHC Class I and Class II antigens and also minor antigens such as H-Y and HA-1 (HLA-A2 restricted). The production of the IL-1 family of cytokines has been associated with the incidence and severity of aGVHD. Therefore, the three IL-1 proteins (IL-1 alpha, IL-1 beta and IL-1Ra) were measured in MLR culture supernatants from HLA-matched sibling (n = 47) patient donor pairs, matched unrelated (n = 13) patient donor pairs that were 6/6 antigens matched and also combinations of HLA-mismatched normal volunteers (n = 21) which included both HLA Class I and II mismatches. 1 x 10(6) cells of stimulator and responder cells/ml were cultured for 7 days at 37 ºC with 5% CO2. The supernatants from these cultures were frozen at -80 ºC prior to cytokine measurement. A paired antibody ELISA was used to detect IL-1 alpha and IL-1Ra, with their respective recombinant human protein as standard (NIBSC, Potters bar, UK). IL-1 beta was measured using an ELISA set. The data obtained for each of the 3 groups was tested for normality and the appropriate statistical testing was carried out. High IL-1 alpha levels were detected in HLA-mismatched MLR supernatants compared to the HLA-matched sibling MLR supernatants (p = <0.0001, MWU) and MUD MLR supernatants (p = 0.0583). There was no significant difference between IL-1 beta levels between the 3 groups studied. There were lower IL-1Ra levels in HLAmismatched MLR culture supernatants compared to HLAmatched sibling MLR cultures (p = 0.0001, unpaired t test) and MUD MLR cultures (p = 0.0065, unpaired t test)(see figure below). There was no significant difference between IL-1Ra levels in MLR supernatants between the sibling and MUD groups studied. The skew of data observed in the HLA-matched sibling cohort could not be attributed to sex mismatch between patients and donors or mismatches between patients and donors for HA-1 due to a lack of HLA-A2 patients. These results illustrate for the first time how HLA-mismatching may influence the production of IL-1 family cytokines, which have been implicated in the pathogenesis of GVHD following BMT. The exact role of HLA Class I, II and minor antigen mismatches on cytokine production still remain to be fully elucidated.
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The relation between T-helper subsets and the risk of graftversus-host disease after allogeneic hematopoietic stem cell transplantation M. Ozcan, P. Topcuoglu, M. Beksac, K. Dalva (Ankara, TR) Graft versus host disease (GVHD) is the most important reason of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (AHSCT). Though a relation between the risk of GVHD and the imbalance of Thelper1(Th1)/Thelper (Th2) cells was reported, there are some conflicting reports on this issue. In this study, our aims were to investigate the balance between of Th1(IFNa, IL2 and TNFa)/Th2 (IL4, IL5 and IL10) after AHSCT;to pursue the expression of the intracellular cytokines according to stem cell source (Peripheral Blood [PB] vs Bone Marrow [BM]); and to evaluate whether any relation between the expression of cytokines and the transplantation outcome does exist. Twentythree consecutive patients (14 M/9F) with various hematological malignancies who underwent Allo-HSCT from their HLA identical sibling donors were enrolled this study. Median age was 29 years (14-45 years).Blood samples were drawn on engraftment day(S1) and day + 100(S2). The expression of cytokines was analyzed and measured by flow cytometrical procedure. In all patients, only the ratio of CD27+ cells significantly decreased at S2 compared to at S1 (12% vs 4.6%, p=0.03), which was more pronounced in PB (14.6% vs 4.3%, p=0.05) group than BMT group (7.1% vs 4.9%, p=0.62). There were important changes on the expression of Th1 cytokines, while the levels of Th2 cytokines remained stable in all patients. At S1 the percentage of CD4+/IL2+ cells were higher in ABMT group than in APSCT group, and the percentages of CD4+/TNFa+ cells were tended to be higher in APSCT group than in ABMT at S2. On day 100, in BMT group CD4+/IL2+ cells decreased from 20.4% to 8.1% (p=0.07). In patients who developed grade II-IV acute GVHD, the ratio of CD4+, CD4+/CD27-, CD4+/IL2+ and CD4+/TNFa+ cells at S1 were found to be significantly higher compared to patients who did not develop GVHD. Three patients died of early transplant-related mortality (TRM). At S1, both TNFa+ and IL2+ cells were higher in patients died of TRM compared to surviving patients. In conclusion, in all patients CD27+ cells decreased on S2 indicating a challenge in immune system due to various stimulators such as GVHD. We observed significant CD4+/TNFa+ cells preponderance at S1 patients who developed acute GVHD later. Similarly CD4+/IFNg+ cells were tended to be higher at S2 in patients who developed chronic GVHD. Our findings should be evaluated in larger series for obtaining prognostic and predictive information about the risk and the severity of GVHD.
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Gene-modified primary donor T-cells administered with a Tcell depleted bone marrow graft circulate more than five years after transplantation C. Ferrand, J.M. Certoux, P. Mercier, E. Robinet, D. Sauce, M. Deschamps, A. Duperrier, E. Deconinck, N. Milpied, B. Lioure, J.Y. Cahn, P. Tiberghien (Besançon, Nantes, Strasbourg, F) Administration of Herpes Simplex-thymidine kinase (HS-tk)-expressing T cells with a T-cell-depleted (TCD) hematopoietic graft can contribute to modulate post-transplant alloreactivity. Twelve patients with an HLA-identical sibling graft received in a phase I-II trial a small number of HS-tk-expressing donor T-cells with a TCD graft (Tiberghien et al, Blood 2001) . Quantitative PCR revealed the presence of circulating gene-modified T-cells (cGMTC) in all patients. After an early increase, the number of cGMTC subsequently progressively decreased over the first year. GCV treatment resulted in rapid 80 to 98% decrease in cGMTC number. A fraction of cGMTc, increasing after GCV treatment, contained a truncated non-functional HS-tk gene (Garin et al, Blood 2001) . Four recipients are alive, off immunosuppression and free of chronic GvHD, 5.5 to 5.8 years after BMT and infusion of 6.105 CD3+ GMTC/kg. Two patients have received prior GCV treatment. Long-term circulation and numbers of cGMTC, transgene expression, presence of the truncated HS-tk gene and GMTC T -cell clonality have been assessed. A stable and quantifiable number of cGMTC were found in all 4 patients from 2 to 5.8 years post BMT thus demonstrating that mature donor T -cells infused with an allogeneic hematopoietic graft can circulate several years after BMT. The absolute number of cGMTC as assessed by quantitative PCR, was 0.05 to 1.106 cGMTC/ L while the % of cGMTC among circulating mononuclear cells was of 0.001 to 0.01%. These donor T -cells infused at time of BMT are apparently tolerant to the recipient. After ex-vivo expansion of PBMC collected 4 to 5 years after BMT, cGMTC were successfully re-selected with 84 +/-7% (n=3) NeoR+ cells after G-418 exposure, thus demonstrating transgene expression in at least a fraction of cGMTC. Both functional and non-functional HS-tk genes were detectable and independently of prior GCV treatment. Lastly, in view of a leukemia occurrence possibly associated with insertional mutagenesis reported in a SCID gene therapy trial (Fisher et al, Paris) and in a murine model (Li et al, Science 2002) , absence of T -cell clonality in re-selected cGMTCs was verified and confirmed. Overall, our results demonstrate that the infusion of a limited number of HS-tk/NeoR donor T-cells at time of BMT can result in the long-term (> 5 years) survival of a stable low number of gene-modified donor Tcells independently of prior GCV treatment
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Function of HSV-TK suicide gene transduced canine lymphocytes M. Weber, W. Guenther, M. Franz, C. Bonini, E. Weissinger, H.-J. Kolb (Munich, D; Milan, I; Hannover, D) Adoptive immunotherapy with donor lymphocyte infusion after stem cell transplantation is the treatment of choice for a number of haematological disorders. The use of donor T cells is limited by graft versus host disease (GvHD). One way to control GvHD is the use of a suicide gene. Here we describe to production, functional analysis and transfusion of canine T cells transduced with the HSV-Tk suicide gene. Transduction was performed using PG13 packaging cell line, stimulation with 5 µg/ml PHA-M and 100 U/ml IL-2, followed twice by spin-inoculation on fibronectin coated-plates. On day 8 the transduced T cells were purified with immunomagnetic beads against LNGFR. More than 95% of the cells were positive for LNGFR expression. Cells were susceptible to the treatment with ganciclovir in therapeutic concentrations. Alloreactivity of the gene modified cells were not significantly lower than those of non-transduced T cells and fresh T cells. We generated gene modified CTLs against DLA and tested the cells in vitro. PBMC were immunized and restimulated at day 8 and 12. Beginning on day 13 the CTLs were transduced according to the described protocol. The capacity of gene modified CTLs to suppress the growth of PHA-blasts was shown in a Delta-Assay. Target cells were plated in a serial dilution, stimulated with 5 µg/ml PHA-M and incubated with irradiated CTLs. After 4 days the 3H-thymidine uptake of the target cells was measured and compared to the control. The results showed a highly specific suppression of the growth of PHA-blasts incubated with gene modified CTLs. At an E/T ratio of 1.25 to 1 we measured a growth suppression of 96.7% (± 2.88%) compared to the control. CTLs not transduced with the HSV-TK suicide gene but otherwise treated in the same way as transduced cells resulted in a growth suppression of 97.3% (± 0.48%). First in vivo results were obtained in a DLA-identical setting with gene modified T cells. One animal was transplanted with bone marrow from its DLA-identical littermate. 80 days after BMT 6.8 x 10(6)/kg gene modified cells were infused into the host. These cells were able to convert the chimerism from mixed to full donor rapidly without inducing GvHD. The gene modified cells were capable of transferring immunity to diphtheria toxin from the donor to the host. The gene modified cells were detectable for at least 220 days in the blood. On the basis of these results will be develop an experimental canine GvHD model with gene modified T cells. D. Sauce, N. Rufer, M. Bodinier, P. Mercier, A. Duperrier, C. Ferrand, P. Herve, P. Romero, F. Lang, P. Tiberghien, E. Robinet (Besançon, F; Lausanne, CH; Nantes, F) To modulate alloreactivity after hematopoietic stem cell transplantation, ''suicide'' gene-modified donor T cells (GMC) are administered with an allogeneic T -cell-depleted bone marrow graft . We have previously demonstrated that such GMC had an impaired Epstein-Barr Virus (EBV) reactivity, that may lead to an altered control of EBV-induced B-cell lymphoproliferation (Sauce et al., Blood 2002; 99: 1165-73) . To further characterize the antiviral potential of gene-modified CD8 T cells, we evaluated, by tetramer staining and IFN-g elispot assay, the frequency of CMVspecific CD8+ cells and directly compared it to the frequency of EBV-specific CD8+ cells within GMC from EBV-and CMVdouble seropositive donors. Interestingly, whereas it alters the anti-EBV response, GMC preparation did not alter the frequency of the anti-CMV response. Several functional and phenotypic differences between both antiviral T cells may contribute to such results. CMV-specific T cells exhibited, during the first days of culture, significantly lower levels of CD3-mediated apoptosis than did EBV-specific T cells (37.0+/-4.5% vs 64.6+/-2.0%, respectively, 24hrs after CD3 activation; p=0.006). In addition, the remaining CMV-specific T-cells that escaped initial apoptosis subsequently exhibited a 1.8-to 11.9-fold higher expansion rate than did anti-EBV T cells (p=0.042). Furthermore, we observed that the CMV-and EBV-specific CD8 cells were of different phenotypes, the former exhibiting mainly (43.2+/-7.2% of tetramer + T -cells) a CD45RA+ CD27-CCR7-terminally differentiated effector phenotype and the latter mainly (53.6+/-5.7%) a CD45RA-CD27+ CCR7-memory phenotype. The phenotype of CMV-and EBV-specific T cells did not account per se for their differential sensitivity to apoptosis but correlated with their differential proliferative potential. Overall, ex vivo T -cell culture conditions differentially affect apoptosis and long-term proliferation of EBV-and CMV-specific T cells. Thus, polyclonal T-cell activation, expansion and gene-transfer processes may result in a cell population with a "skewed" antiviral potential, which could have a significant clinical impact. Ex-vivo gene transfer protocols need to be improved in order to maintain a broad antigenic repertoire.
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Retroviral-mediated gene transfer in polyclonal CD8 T-cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive cells as compared to EBVreactive cells
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Use of pegfilgrastim for autologous peripheral blood stem cell mobilization: comparison to a daily filgrastim regimen S. Noga, M. Oroszlan, J. Hetherington, M. Feldman, H. Saiontz, M Kassa, J. Bosley, J. Nuckols, R. Baynes (Baltimore, Thousand Oaks, USA) Daily growth factor mobilization regimens create significant issues in terms of patient satisfaction/ compliance, cost and outpatient clinic utilization. A recently introduced human recombinant, pegylated G -CSF [pegfilgrastim (PF), Neulasta (R),Amgen,Inc] remains at therapeutic levels for 2 weeks after a single, fixed dose, SC injection. We report preliminary data using PF for the mobilization of autologous peripheral blood stem cell (PBSC). Five patients (median age: 59 years) with hematologic malignancies underwent PBSC mobilization using cyclophosphamide, 2.5 g/m2 (assigned as day +1). On day +2, a single 6mg SC injection of PF was administered. Results were compared to 50 consecutive patients undergoing an identical mobilization regimen that used filgrastim [(F), Neupogen (R), Amgen,Inc] at 10 mcg/kg SC q day until the last day of collection. PF patients showed an increase in the white blood cell (WBC) count on day +3/+4 (10,000 to 29,000/ul) followed by the expected nadir (day +7 to +9). Starting on day +7, patients had daily WBC, differential and absolute peripheral blood (PB) CD34 counts performed until the last day of PBSC collection. Apheresis was started the day immediately following a WBC >1,000/ul or an absolute PB CD34 count >20/ul (median day +11). PB CD34 averaged 55/ul (range 10 to 280):PF vs. 54/ul:F during the days of apheresis. PF patients were collected on 2 consecutive days using a Cobe Spectra (v7.0, Gambro BCT, Inc) for maximum 3 blood volumes and flow rate of 80-100 ml/min. The F cohort were all collected in 1 day using a Cobe Spectra (v6.0) and high flow/volume apheresis (maximum 6 blood volumes) at a flow rate of 150 ml/min. PB of PF patients drawn immediately after the PBSC collection on the 1st day of collection showed almost no fall in WBC or PB CD34 counts even after 4 hours of collection. The mean day 1 collection was 9.2 (11.3 SD) x10E6 CD34/kg vs. 10.7 (7.1) x10E6/kg for PF and F mobilization, respectively. PF patients also received a single SC injection of F (10 mcg/kg) on the evening following the first PBSC collection. The second day of collection averaged 8.4x10E6 (7.2) CD34/kg. Myalgias/arthralgias were the o nly reported side effects in 3 patients starting the day before collection. We conclude that PF can successfully mobilize high yields of PBSC following chemotherapy priming using standard apheresis procedures. Future studies will investigate optimal dosing, use of PF alone and also whether F can be omitted after the 1st apheresis.
Oral Session: Late effects and Quality of life O167
Chronic GVHD is reduced with prophylactic anti-thymocyte globulin in alternative donor transplants A. Bacigalupo, T. Lamparelli, F. Gualandi, S. Bregante, A.M. Raiola, C. Di Grazia, A. Dominietto, F. Frassoni, E. Tedone, D. Occhini, M.T. van Lint (Genoa, I) Background. Chronic GvHD remains a major complication of alternative donor transplants, and it is uncertain how this late complication can best be prevented. Objective. To study the impact of preparative regimens with or without anti-thymocyte globulin (ATG) on chronic graft versus host disease (GvHD) in 160 patients undergoing a marrow transplants from unrelated donors (n=127) or partially mismatched family donors (n=33). Methods. Rabbit ATG (Thymoglobuline, Sangstat) ,7.5-15 mg/kg was given within the conditioning regimen to 102 patients, whereas 58 patients received no ATG. The median age was 34 years for the ATG group and 29 and for the non-ATG group (p=0.002); otherwise the two groups were matched for disease phase , diagnosis, donor age, interval diagnosis transplant, and number of cells infused at the time of transplant. Median follow up for surviving patients is 4.5 years (range 1.5-9). The conditioning regimen was cyclophosphamide (CY) and total body irradiation (TBI) in 95 and CY-Thiotepa in 65 patients, the source of stem cells was bone marrow for all patients. Results. Acute GvHD grade II-IV and grade III-IV was reduced in patients receiving ATG (51% vs 74%, p=0.004 and 14% vs 28%, p=0.03 respectively). In the ATG group there were significantly less patients with chronic GvHD at 6 months (14% vs 30% p=0.03), one year (7% vs 41% p=0.0001) 2 years (16% vs 36%, p=0.02) 4 years (6% vs 39%, p= 0.002) and beyond 4 years (0% in 19 patients at risk vs 30% in 24 patients at risk, p=0.01). In the ATG group there were more patients with a performance status (Karnowski score) greater than 90 at last follow up (93% vs 56% , p=0.01) and more patient off cyclosporin two year post transplant (28% vs 3%, p=0.003). Survival in the ATG/non-ATG groups was comparable for patients receiving TBI (56% vs 59%,p=0.7) and for patient receiving thiotepa (33% vs 18%,p=0.3), as well as transplant mortality and relapse. Conclusions. We conclude that ATG pre-transplant reduces the risk of acute and chronic GvHD, improves quality of life and increases the likelihood to discontinue immunosuppressive therapy. This also suggests that in vivo T cell depletion pretransplant has a major impact on chronic GvHD many years post-transplant.
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Long-term follow-up after stem cell transplantation for chronic myeloid leukemia in 1st chronic phase M. Yeshurun, P. Guardiola, A. Devergie, L. Ades, P. Ribaud, H. Esperou, E. Gluckman, G. Socié (Paris, F) While allogeneic Stem Cell Transplantation (SCT) for Chronic Myeloid Leukemia (CML) 1st Chronic Phase (CP), has been one of the main indication of transplantation before the STI era, surprisingly few data are available on the long-term outcomes on such transplant and on the rates and risk factors (RF) of late complications. From 1982 to 1998, 103 patients (pts) underwent non-manipulated SCT for CML 1st CP from a sibling donor in our center (median follow-up 6.5 years, range, 1.7-18.1 years). Median age at transplant was 36 years (range, 8-56 years). 43 pts have been previously treated with IFN. Sokal's score at diagnosis was low in 66 pts, intermediate in 15 pts, and high in 14 pts (missing, 8) . BuCY was used in 63% and Cy-TBI in 37% of the pts for conditioning. All pts received CsA for GvHD prophylaxis (CsA+MTX in 78 pts). The 7-year estimated survival was 57% (95%CI: 48-67%). The 7-year relapse (cytogenetic or hematological) and TRM incidences were 5% and 37%. In multivariate analysis, pre-transplant-RF associated with decreased survival and increased TRM were older age, GvHD prophylaxis with CsA alone, and absence of hematological remission before SCT. Post-transplant-RF associated with survival and TRM included steroid-resistant GvHD and fungal infections. 7-year chronic GvHD incidence rate was 71% and was associated with splenectomy, PBSC, acute GvHD, and CMV infection, in multivariate analysis. 7-year estimated incidences of cataract, osteonecrosis, thyroid dysfunction, osteoporosis bacterial infections and depression were 46%, 57%, 22%, 15%, 11%, 46%, and 32%. 5 patients developed a solid tumor. RF associated (multivariate analyses) with cataract, depression and bone diseases was extensive chronic GvHD.
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Single center evaluation of thyroid function abnormalities following hematopoetic stem cell transplant S. Kulkarni, R. Powles, B. Sirohi, J. Brennan, J. Treleaven, R. Saso, S. Sankpal, J. Metha, S. Singhal, M. Ortin, C. Pinkerton, C. Horton (Sutton, UK) The prospectively maintained database at this hospital identified 1560 patients who received allogeneic (n=1050,M: 616, F:434, median age:27, range:0-56 yr.), autologous (n=486, M:293, F:193; median age:31, range:1-74) or syngeneic transplant (n=24, M:14, F:10; median age:33, range:2-65 yr.). These patients were evaluated to identify the incidence and risk factors for the development of thyroid gland hypo function. All patients who had biochemical evidence of hypothyroidism were included in the analysis. Transplants w ere done for acute leukaemia (n=1179), chronic leukaemia (n=184) or other haematological disorders (n=197). Conditioning therapy was with TBI in 1187 patients and with chemotherapy in 373 patients. The donor was HLA identical sibling in 877 patients, matched unrelated donor in 121 and mismatched family member in 52 cases. For allograft patients GVHP consisted of CyA in 522 cases CyA+Mtx in 483 cases and other measures in 45 cases. Disease stage was good risk in 855 patients and poor risk in 705 cases. 62 patients developed thyroid dysfunction (27 allograft, 35 autograft). The risk of thyroid dysfunction was 10% at 10 yr. Thyroid dysfunction developed at a median of 4.1 yr. (range:0.3-12 yr.). In univariate analysis, thyroid dysfunction was significantly higher for patients younger than 16yr. age (20% vs. 5%, p<0.0001), autograft (13% vs. 3%, p<0.0001), TBI conditioning (13% vs. 5%, p=0.035), TBI dose >9,5 Gy. (15% vs. 4%, p=0.0006), acute GVHD (5% vs. 2%, p=0.03). There was no effect of patient sex, source of stem cells, donor sex, and patient/donor blood group match. In multivariate analysis, age <16 yr. (RR: 4.1, 95% CI: 2.44-6.8,
